Weight? Wait! Don't tell me.

When payers (most notably Medicare) look at GLP-1 receptor agonists, they see only the cost. That ’s like the FDA reviewing risks while ignoring benefits when considering new medicines. It has to be about value. And when it comes to measuring value, we must embrace a comprehensive view of cost and benefit. Regarding GLP-1 receptor agonists, the proper denominator isn’t cost; it’s value. Ch oosing only to only discuss costs without context is dishonest and deleterious to public health.
Source: drugwonks.com Blog - Category: Pharmaceuticals Source Type: blogs